文献速递传染病防控与疫情报告

重新评估法匹拉韦治疗狂犬病毒感染的效果

Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
PubMed 文献 · Vaccine · 2017-11-10

本研究在体外和小鼠模型体内重新评估了法匹拉韦(T-705)抗狂犬病毒的效果。体外法匹拉韦有效减少狂犬病毒复制;体内预防和治疗给药效果有限,仅在高剂量病毒肌内注射时延迟临床体征出现,低剂量时减少出现临床体征的小鼠数,治疗开始日期对结果无统计学显著影响。作者认为单药使用可能有限,需进一步研究其作为多药治疗组分的协同效应。

要点

  • 体外法匹拉韦有效减少狂犬病毒复制。
  • 体内高剂量病毒肌内注射时法匹拉韦延迟临床体征出现。
  • 体内低剂量病毒时法匹拉韦减少出现临床体征的小鼠数。

核心结论

  • 法匹拉韦单药作为生物实体用于治疗狂犬病毒感染可能有限。
  • 作者认为需进一步研究法匹拉韦作为多药治疗组分治疗人类狂犬感染的协同效应。

研究设计与样本

  • 体外实验评估法匹拉韦抗狂犬病毒效果。
  • 小鼠模型体内实验采用腹腔给药,评估暴露前和暴露后多种给药方案。

主要发现

  • 体外法匹拉韦有效减少狂犬病毒复制。
  • 体内高剂量病毒(10^6.8 TCID50/ml)肌内注射时,法匹拉韦治疗延迟临床体征出现。
  • 体内低剂量病毒(10^5.8 TCID50/ml)时,法匹拉韦在观察期内减少出现临床体征的小鼠数。
  • 两个实验中治疗开始日期对结果均无统计学显著影响。

局限性

  • 体内效果有限。
  • 作者认为法匹拉韦单药使用可能有限。
  • 作者认为需进一步研究法匹拉韦作为多药治疗组分的协同效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is no antiviral treatment available once clinical disease following rabies virus infection has initiated. Considered a neglected tropical disease, >60,000 human rabies deaths are estimated each year despite the availability of pre- and post-exposure prophylaxis for pre-immunisation or administration following a potential exposure before the onset of clinical disease. Such post-exposure treatments include administration of rabies immunoglobulin (RIG) and vaccination at a distant site to prime a humoral immune response. However, current therapeutic options are limited. Regardless there is a need for molecules that target virus infection following the onset of clinical disease where the outcome of infection is invariably fatal. Numerous molecules have been assessed as potential antivirals against rabies virus (RABV) but with little promise. Favipiravir (T-705) is a broad-spectrum RNA polymerase inhibitor, which has been shown to have antiviral activity against a range of RNA viruses including some against RABV. In the present study, the utility of T-705 has been reassessed in vitro as well as in vivo in a murine model using intraperitoneal administration to investigate any immune protective effect of the molecule. In vitro T-705 effectively reduces RABV replication. However, in vivo, following assessment of various applications of the molecule in both pre- and post-exposure scenarios, the effect was limited. T-705 treatment delayed the onset of clinical signs when virus was delivered intramuscularly at a higher dose (106.8 TCID50/ml) and reduced the number of mice that developed clinical signs when virus was delivered at a lower dose (105.8 TCID50/ml) during the observation period. The day at which treatment commenced did not appear to have a statistically significant effect on the results in either experiment. The use of T-705 as a single biological entity may be limited, however, further work is required to assess the synergistic effect of T-705 as a component of a multi-drug therapy for treating human rabies infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Banyard AC, Mansfield KL, Wu G, et al. Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Vaccine. 2017. PMID: 29132993. doi:10.1016/j.vaccine.2017.10.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。